Literature DB >> 21283108

Emerging therapeutic opportunities for skeletal restoration.

Masanobu Kawai1, Ulrike I Mödder, Sundeep Khosla, Clifford J Rosen.   

Abstract

Osteoporosis, a syndrome characterized by thin bones and fractures, has become more prevalent in both women and men. Established therapies for treating this disorder consist primarily of drugs that prevent bone loss, such as the bisphosphonates and selective oestrogen receptor modulators. Although these drugs have been shown to reduce fractures in randomized trials, there is an urgent need for treatments that could lower fracture risk further without additional adverse effects. The introduction of parathyroid hormone (teriparatide), which significantly increases bone mineral density, albeit for a relatively short duration, raised expectations that drugs that stimulate bone formation might cure osteoporosis. After outlining current approaches for treating osteoporosis, this Review focuses on emerging therapeutic opportunities for osteoporosis that are based on recent insights into skeletal physiology. Such novel strategies offer promise not only for reducing age-related bone loss and the associated risk of fractures but also for restoring bone mineral density to healthy levels.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21283108      PMCID: PMC3135105          DOI: 10.1038/nrd3299

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


  175 in total

1.  Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.

Authors:  W S Simonet; D L Lacey; C R Dunstan; M Kelley; M S Chang; R Lüthy; H Q Nguyen; S Wooden; L Bennett; T Boone; G Shimamoto; M DeRose; R Elliott; A Colombero; H L Tan; G Trail; J Sullivan; E Davy; N Bucay; L Renshaw-Gegg; T M Hughes; D Hill; W Pattison; P Campbell; S Sander; G Van; J Tarpley; P Derby; R Lee; W J Boyle
Journal:  Cell       Date:  1997-04-18       Impact factor: 41.582

Review 2.  Accelerated osteoporosis in psychiatric patients: possible pathophysiological processes.

Authors:  U Halbreich; S Palter
Journal:  Schizophr Bull       Date:  1996       Impact factor: 9.306

Review 3.  Insulin-like growth factors and their binding proteins: biological actions.

Authors:  J I Jones; D R Clemmons
Journal:  Endocr Rev       Date:  1995-02       Impact factor: 19.871

4.  Dickkopf-1 is a member of a new family of secreted proteins and functions in head induction.

Authors:  A Glinka; W Wu; H Delius; A P Monaghan; C Blumenstock; C Niehrs
Journal:  Nature       Date:  1998-01-22       Impact factor: 49.962

5.  Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects.

Authors:  S L Suter; J J Nolan; P Wallace; B Gumbiner; J M Olefsky
Journal:  Diabetes Care       Date:  1992-02       Impact factor: 19.112

6.  Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r).

Authors:  J P Liu; J Baker; A S Perkins; E J Robertson; A Efstratiadis
Journal:  Cell       Date:  1993-10-08       Impact factor: 41.582

7.  Biochemical hyperparathyroidism and bone mineral status in patients treated long-term with lithium.

Authors:  J Nordenström; M Elvius; M Bågedahl-Strindlund; B Zhao; O Törring
Journal:  Metabolism       Date:  1994-12       Impact factor: 8.694

8.  Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone.

Authors:  J J Nolan; B Ludvik; P Beerdsen; M Joyce; J Olefsky
Journal:  N Engl J Med       Date:  1994-11-03       Impact factor: 91.245

Review 9.  Biochemical markers of bone turnover.

Authors:  P D Delmas
Journal:  J Bone Miner Res       Date:  1993-12       Impact factor: 6.741

10.  Effects of recombinant insulin-like growth factor-I and growth hormone on bone turnover in elderly women.

Authors:  L J Ghiron; J L Thompson; L Holloway; R L Hintz; G E Butterfield; A R Hoffman; R Marcus
Journal:  J Bone Miner Res       Date:  1995-12       Impact factor: 6.741

View more
  48 in total

1.  A2B adenosine receptor promotes mesenchymal stem cell differentiation to osteoblasts and bone formation in vivo.

Authors:  Shannon H Carroll; Nathan A Wigner; Nitin Kulkarni; Hillary Johnston-Cox; Louis C Gerstenfeld; Katya Ravid
Journal:  J Biol Chem       Date:  2012-03-08       Impact factor: 5.157

2.  A Novel, Direct NO Donor Regulates Osteoblast and Osteoclast Functions and Increases Bone Mass in Ovariectomized Mice.

Authors:  Hema Kalyanaraman; Ghania Ramdani; Jisha Joshua; Nadine Schall; Gerry R Boss; Esther Cory; Robert L Sah; Darren E Casteel; Renate B Pilz
Journal:  J Bone Miner Res       Date:  2016-09-07       Impact factor: 6.741

3.  Protective effect of myo-inositol hexaphosphate (phytate) on bone mass loss in postmenopausal women.

Authors:  Angel A López-González; Félix Grases; Nieves Monroy; Bartolome Marí; Ma Teófila Vicente-Herrero; Fernando Tur; Joan Perelló
Journal:  Eur J Nutr       Date:  2012-05-22       Impact factor: 5.614

4.  Bone diseases: SEMA3A strikes a balance in bone homeostasis.

Authors:  Man Tsuey Tse
Journal:  Nat Rev Drug Discov       Date:  2012-05-18       Impact factor: 84.694

5.  Chrysin promotes osteogenic differentiation via ERK/MAPK activation.

Authors:  Wenfeng Zeng; Yan Yan; Fayun Zhang; Chunling Zhang; Wei Liang
Journal:  Protein Cell       Date:  2013-06-06       Impact factor: 14.870

6.  Osteoporosis: The Result of an 'Aged' Bone Microenvironment.

Authors:  Bo Yu; Cun-Yu Wang
Journal:  Trends Mol Med       Date:  2016-06-26       Impact factor: 11.951

7.  Regulators of G protein signaling 12 promotes osteoclastogenesis in bone remodeling and pathological bone loss.

Authors:  X Yuan; J Cao; T Liu; Y-P Li; F Scannapieco; X He; M J Oursler; X Zhang; J Vacher; C Li; D Olson; S Yang
Journal:  Cell Death Differ       Date:  2015-04-24       Impact factor: 15.828

8.  Impact and risk factors of post-stroke bone fracture.

Authors:  Kang Huo; Syed I Hashim; Kimberley L Y Yong; Hua Su; Qiu-Min Qu
Journal:  World J Exp Med       Date:  2016-02-20

9.  Ezrin-anchored protein kinase A coordinates phosphorylation-dependent disassembly of a NHERF1 ternary complex to regulate hormone-sensitive phosphate transport.

Authors:  Bin Wang; Chris K Means; Yanmei Yang; Tatyana Mamonova; Alessandro Bisello; Daniel L Altschuler; John D Scott; Peter A Friedman
Journal:  J Biol Chem       Date:  2012-05-24       Impact factor: 5.157

Review 10.  Osteoblast dysfunctions in bone diseases: from cellular and molecular mechanisms to therapeutic strategies.

Authors:  Pierre J Marie
Journal:  Cell Mol Life Sci       Date:  2014-12-09       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.